A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice
Authors:
- Ulf NeumannUNUlf Neumann
- Heinrich RueegerHRHeinrich Rueeger
- Rainer MachauerRMRainer Machauer
- Siem Jacob VeenstraSVSiem Jacob Veenstra
- Rainer M. LueoendRLRainer M. Lueoend
- Marina Tintelnot-BlomleyMTMarina Tintelnot-Blomley
- Grit LaueGLGrit Laue
- Karen BeltzKBKaren Beltz
- Barbara VoggBVBarbara Vogg
- Peter SchmidPSPeter Schmid
- Wilfried FrieauffWFWilfried Frieauff
- Derya R. ShimshekDSDerya R. Shimshek
Open Access
- 3 September 2015
- journal article
- research article
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 10 (1) , 1-15
Abstract
Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD. Approaches to target Aβ via inhibition of γ-secretase or passive antibody therapy have not yet resulted in substantial clinical benefits. Inhibition of BACE1 (β-secretase) has proven a challenging concept, but recent BACE1inhibitors can enter the brain sufficiently well to lower Aβ. However, failures with the first clinical BACE1 inhibitors have highlighted the need to generate compounds with appropriate efficacy and safety profiles, since long treatment periods are expected to be necessary in humans. Treatment with NB-360, a potent and brain penetrable BACE-1 inhibitor can completely block the progression of Aβ deposition in the brains of APP transgenic mice, a model for amyloid pathology. We furthermore show that almost complete reduction of Aβ was achieved also in rats and in dogs, suggesting that these findings are translational across species and can be extrapolated to humans. Amyloid pathology may be an initial step in a complex pathological cascade; therefore we investigated the effect of BACE-1 inhibition on neuroinflammation, a prominent downstream feature of the disease. NB-360 stopped accumulation of activated inflammatory cells in the brains of APP transgenic mice. Upon chronic treatment of APP transgenic mice, patches of grey hairs appeared. In a rapidly developing field, the data on NB-360 broaden the chemical space and expand knowledge on the properties that are needed to make a BACE-1 inhibitor potent and safe enough for long-term use in patients. Due to its excellent brain penetration, reasonable oral doses of NB-360 were sufficient to completely block amyloid-β deposition in an APP transgenic mouse model. Data across species suggest similar treatment effects can possibly be achieved in humans. The reduced neuroinflammation upon amyloid reduction by NB-360 treatment supports the notion that targeting amyloid-β pathology can have beneficial downstream effects on the progression of Alzheimer’s disease.Keywords
This publication has 32 references indexed in Scilit:
- Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathologyInternational Journal of Neuroscience, 2013
- Biochemistry of Amyloid -Protein and Amyloid Deposits in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase InhibitorJournal of Neuroscience, 2011
- Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical LiteratureCold Spring Harbor Perspectives in Medicine, 2011
- Neuroglia in neurodegenerationBrain Research Reviews, 2010
- β-Secretase Inhibitor Potency Is Decreased by Aberrant β-Cleavage Location of the “Swedish Mutant” Amyloid Precursor ProteinJournal of Biological Chemistry, 2010
- In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous SystemDrug Metabolism and Disposition, 2008
- High-Throughput Screening of Drug−Brain Tissue Binding and in Silico Prediction for Assessment of Central Nervous System Drug DeliveryJournal of Medicinal Chemistry, 2007
- Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosisNature Neuroscience, 2004
- High-Throughput Permeability pH Profile and High-Throughput Alkane/Water logPwith Artificial MembranesJournal of Medicinal Chemistry, 2001